• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise

cafead

Administrator
Staff member
  • cafead   Sep 06, 2023 at 10:12: AM
via Less than one year after selling an experimental medicine to Takeda for $4 billion, Nimbus Therapeutics is reloading with new funding meant to support its next wave of drug candidates, among them a prospective cancer therapy.

article source
 

<